AstraZeneca invests in e-business intelligence solution

16 May 2001

In order to transform the way in which its pharmaceutical developmentteams capture, share and exploit critical scientific data, AstraZeneca has signed a contract with e-business intelligence solutions provider Business Objects for use of its BusinessObjects integrated query, reporting and online analytical processing tool.

AstraZeneca plans to use BusinessObjects to support many of its primary R&D functions, including reporting on clinical trials, drug safety and project budgeting. The e-BI firm is also providing it with training, implementation and development support.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight